ClinicalTrials.gg
RecruitingNCT03711539MASTER@HEARTUpdated Jul 3, 2024

Lifetime Endurance Exercise to Prevent Coronary Artery Disease

An observational study in Coronary Artery Disease, Physical Activity and Lifestyle, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 3 sites in Belgium. Open to male participants aged 45 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

How we know

From the registry’s dates

  • Started Oct 2018; still recruiting 8 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,800
Ages
45 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven — 4 open to participants now, 4 under way, none of them phase 3. Coronary Artery Disease · Universitaire Ziekenhuizen KU Leuven.

Started
2018
the only one that year
Observational
4 of 10
2 open now
Registered
6th of 10
by date

Among the 10 studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven, this one is the only one that started in 2018, is one of 4 observational ones, and was the 6th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

4 of the 10 studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 45 Years to 70 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Coronary Artery Disease by Universitaire Ziekenhuizen KU Leuven, or all of them as a file.
02

Study summary

The primary objective of the Master@Heart Trial is to investigate whether lifelong endurance exercise reduces the incidence of non-calcified plaques (both mixed and soft plaques) as compared to late-onset endurance exercise and a non-athletic lifestyle.

Read the detailed description

Cardiovascular disease remains the leading cause of death in Europe and is strongly related to a sedentary lifestyle combined with inadequate dietary habits and the prevalence of smoking. In parallel with this modern inactivity pandemic, the past 2 decades we have also witnessed an increase in the number of middle-aged and older individuals engaging in competitive sports and mass exercise events, such as marathon-running and cycling events. This increasing popularity of endurance sports implies that a greater proportion of individuals participating in high-intensity sport will have a higher cardiovascular risk profile. Coronary artery disease is by far the most common cause of sudden cardiac death in senior athletes, accounting for >75% of all cardiac deaths during exercise. Each case of sudden cardiac death is always a dramatic event and is often widely publicized in the media, thereby raising issues and questions regarding the safety of intense sports participation. Debate and uncertainty persist with much speculation filling the space left by an incomplete understanding of the exercise dose-response relationship. In view of the importance of exercise for healthy ageing, it is important to identify and eliminate any adverse associations with exercise so that everyone can enjoy the benefits of exercise. Until present, no studies have compared the 'standard of care,' which includes a healthy diet, abstinence from smoking, and regular moderate exercise, with and without the addition of larger doses of endurance exercise. Furthermore, it remains unknown whether the age of onset of endurance training influences its potential preventive and adverse effects.

Until present, no studies have compared the 'standard of care,' which includes a healthy diet, abstinence from smoking, and regular moderate exercise, with and without the addition of long-term endurance exercise. In this multicentre project we will investigate the beneficial effects of long-term endurance exercise for the prevention of coronary and carotid artery disease and its potential adverse effects, such as an increased incidence of atrial fibrillation and myocardial fibrosis. We will recruit 3 age-matched cross-sectional cohorts: (1) lifelong endurance athletes engaged in regular endurance sports practice since the age of 30 years, (2) late-onset endurance athletes who have initiated endurance sports activities after the age of 30 years and (3) non-athletic individuals. Only male subjects will be included given the much lower prevalence of ischemic heart disease amongst female athletes.

03

Conditions studied

  • Coronary Artery Disease
  • Physical Activity
  • Lifestyle

Keywords

  • Endurance Exercise
  • Coronary Artery Disease
  • Atrial Fibrillation
  • Myocardial Fibrosis
  • Coronary CT
04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Cohort 1: Lifelong endurance athletes. Inclusions: Athletes who have initiated endurance sports activities at regional, national or international level before the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing.

Cohort 2: Late-onset endurance athletes. Athletes who have initiated endurance sports activities at regional, national or international level after the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing.

Cohort 3: Healthy non-athletes will be recruited from subjects seen in the outpatient clinic for a work-related medical check-up, from university alumni and from multisports organisations. Participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) >3 hours /week is allowed.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Lifelong endurance athletes:

    • Initiation of endurance sports before the age of 30 years
    • Activities at regional, national or international level
    • Sports: triathlon, cycling, distance running (1500 metres and longer) and rowing
    • Aged 45-70 years
    • Involved in competition and high-level training:

      • more than 10 hours per week for cyclists and triathletes
      • more than 6 hours per week for runners and rowers.
  • Late-onset endurance athletes:

    • Initiation of endurance sports after the age of 30 years and at least 6 months ago
    • Activities at regional, national or international level
    • Sports: triathlon, cycling, distance running (1500 metres and longer) and rowing
    • Aged 45-70 years
    • Involved in competition and high-level training:

      • more than 10 hours per week for cyclists and triathletes
      • more than 6 hours per week for runners and rowers.
  • Healthy non-athletes

    • subjects seen in the outpatient clinic for a work-related medical check-up
    • university alumni
    • subjects from multisports organisations
    • history of regular sports practice \<3 hours /week
    • participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) >3 hours /week is allowed

Exclusion criteria

Exclusion Criteria:

  • history of smoking (> 5 pack years)
  • history of diabetes
  • diagnosis of cardiopulmonary disorder prior to inclusion
  • medical treatment for arterial hypertension or hypercholesterolemia
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,800 participants (estimated)
Patient registry
No

Groups and cohorts

  • Lifelong Endurance Athletes

    i) Athletes who have initiated endurance sports activities at regional, national or international level before the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (\> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.

  • Late-onset Endurance Athletes

    i) Athletes who have initiated endurance sports activities at regional, national or international level after the age of 30 years. Sports include triathlon, cycling, distance running (1500 metres and longer) and rowing. ii) Aged 45-70 years. iii) Involved in competition and high-level training: more than 10 hours per week for cyclists and triathletes or more than 6 hours per week for runners and rowers. Subjects will be excluded if: i) they have a history of smoking (\> 5 pack years) or diabetes, ii) they have a history of smoking (\> 5 pack years) or diabetes, ii) had been diagnosed with a cardiopulmonary disorder prior to inclusion.

  • Healthy Non-athletes

    Healthy non-athletes will be recruited from subjects seen in the outpatient clinic for a work-related medical check-up, from university alumni and from multisports organisations. Subjects will be excluded if they: i) had been involved in regular sports practice more than \>3 hours / week, ii) have a history of smoking (\> 5 pack years) or diabetes, or iii) had been diagnosed with a cardiopulmonary disorder prior to inclusion. Participation in regular sports with a low dynamic component (e.g. billiards, darts or bowling) \>3 hours /week is allowed.

06

What researchers measure

Primary outcomes

  1. Incidence of Non-calcified Plaques

    Incidence of non-calcified plaques (both mixed and soft plaques) assessed by Coronary CT in lifelong endurance athletes as compared to late-onset endurance athletes and non-athletic subjects.

    Time frame: 2 years

Secondary outcomes

  1. Incidence of Atrial Fibrillation

    To assess the association between the (a) amount and (b) starting age of lifelong endurance sports and atrial fibrillation assessed by Holter monitoring

    Time frame: 4 years

  2. Prevalence of Myocardial Fibrosis

    To assess the association between the (a) amount and (b) starting age of lifelong endurance sports and myocardial fibrosis assessed by cardiac magnetic resonance imaging

    Time frame: 2 years

Other outcomes

  1. Arterial Stiffness

    To assess arterial stiffness by Applanation Tonometry in lifelong endurance athletes versus late-onset athletes and non-athletic individuals.

    Time frame: 2 years

  2. Carotid Intima Thickness

    To assess carotid intima thickness by Doppler Ultrasound in lifelong endurance athletes versus late-onset athletes and non-athletic individuals.

    Time frame: 2 years

  3. Left Ventricular Diastolic Function

    To assess left ventricular diastolic function by echocardiography in lifelong endurance athletes versus late-onset athletes and non-athletic individuals.

    Time frame: 2 years

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • De Bosscher R, Dausin C, Claus P, Bogaert J, Dymarkowski S, Goetschalckx K, Ghekiere O, Belmans A, Van De Heyning CM, Van Herck P, Paelinck B, El Addouli H, La Gerche A, Herbots L, Heidbuchel H, Willems R, Claessen G. Endurance exercise and the risk of cardiovascular pathology in men: a comparison between lifelong and late-onset endurance training and a non-athletic lifestyle - rationale and design of the Master@Heart study, a prospective cohort trial. BMJ Open Sport Exerc Med. 2021 Apr 16;7(2):e001048. doi: 10.1136/bmjsem-2021-001048. eCollection 2021. PubMed 33927885 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Oct 2021, 35 months.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's 35 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2018
First posted
Oct 18, 2018
StartActual
Oct 18, 2018
Primary completionActual
Oct 1, 2021
CompletionEst.
Oct 1, 2025
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03711539
Collaborators
University Hospital, Antwerp, Jessa Hospital
Responsible party
Sponsor
First posted
Oct 18, 2018
Start date
Oct 18, 2018
Primary completion
Oct 1, 2021
Completion
Oct 1, 2025 (estimated)
Last update
Jul 3, 2024

Study contacts

Guido Claessen, MD, PhD
Contact
guido.claessen@kuleuven.be
+3216343397

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion